{"id":348452,"date":"2025-08-25T14:30:20","date_gmt":"2025-08-25T14:30:20","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-delcath-systems\/"},"modified":"2025-08-25T14:30:20","modified_gmt":"2025-08-25T14:30:20","slug":"how-to-buy-delcath-systems","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-delcath-systems\/","title":{"rendered":"Delcath Systems, Inc. (DCTH) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Delcath Systems, Inc. (DCTH) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334054,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-348452","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Delcath Systems, Inc. (DCTH) Hisseleri Nas\u0131l Al\u0131n\u0131r - Delcath Systems, Inc. (DCTH) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Delcath Systems, Inc. (DCTH) Hisseleri Nas\u0131l Al\u0131n\u0131r - Delcath Systems, Inc. (DCTH) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Delcath Systems, Inc. (DCTH) hisselerini nas\u0131l alaca\u011f\u0131n\u0131z\u0131 kapsaml\u0131 yat\u0131r\u0131m analizimizle \u00f6\u011frenin. Bu umut vadeden biyoteknoloji hissesi i\u00e7in g\u00fcncel fiyat trendlerini, b\u00fcy\u00fcme f\u0131rsatlar\u0131n\u0131 ve ad\u0131m ad\u0131m sat\u0131n alma rehberini ke\u015ffedin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Delcath Systems, Inc. (DCTH) hisselerini nas\u0131l alaca\u011f\u0131n\u0131z\u0131 kapsaml\u0131 yat\u0131r\u0131m analizimizle \u00f6\u011frenin. Bu umut vadeden biyoteknoloji hissesi i\u00e7in g\u00fcncel fiyat trendlerini, b\u00fcy\u00fcme f\u0131rsatlar\u0131n\u0131 ve ad\u0131m ad\u0131m sat\u0131n alma rehberini ke\u015ffedin."},"intro":"\u0130leri teknoloji kanser tedavi teknolojisine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Delcath Systems, Inc. (DCTH), t\u0131bbi yenilik ve yat\u0131r\u0131m f\u0131rsat\u0131n\u0131n heyecan verici kesi\u015fimini temsil ediyor. Bu \u015firket, kendi geli\u015ftirdi\u011fi da\u011f\u0131t\u0131m sistemleriyle karaci\u011fer kanseri tedavisinde devrim yarat\u0131yor ve ak\u0131ll\u0131 yat\u0131r\u0131mc\u0131lar bunu fark ediyor. Bu potansiyel olarak kazan\u00e7l\u0131 yat\u0131r\u0131m hakk\u0131nda bilmeniz gereken her \u015feyi a\u00e7\u0131klayaca\u011f\u0131z.","intro_source":{"label":"Intro","type":"text","formatted_value":"\u0130leri teknoloji kanser tedavi teknolojisine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Delcath Systems, Inc. (DCTH), t\u0131bbi yenilik ve yat\u0131r\u0131m f\u0131rsat\u0131n\u0131n heyecan verici kesi\u015fimini temsil ediyor. Bu \u015firket, kendi geli\u015ftirdi\u011fi da\u011f\u0131t\u0131m sistemleriyle karaci\u011fer kanseri tedavisinde devrim yarat\u0131yor ve ak\u0131ll\u0131 yat\u0131r\u0131mc\u0131lar bunu fark ediyor. Bu potansiyel olarak kazan\u00e7l\u0131 yat\u0131r\u0131m hakk\u0131nda bilmeniz gereken her \u015feyi a\u00e7\u0131klayaca\u011f\u0131z."},"body_html":"<h2>\ud83d\udcc8 G\u00fcncel Hisse Performans\u0131 ve \u00d6nemli Tarihler<\/h2> <p>25 A\u011fustos 2025 itibar\u0131yla Delcath Systems, Inc. (DCTH) hissesi <strong>11,12 $<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. Bu fiyat, hissenin 52 haftal\u0131k en y\u00fcksek seviyesi olan 18,23 $'\u0131n olduk\u00e7a alt\u0131nda ancak y\u0131ll\u0131k en d\u00fc\u015f\u00fck seviyesi olan 7,83 $'\u0131n \u00fczerinde konumlan\u0131yor.<\/p> <p><strong>Takviminize not edin: 14 Kas\u0131m 2025<\/strong>, DCTH yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in bir sonraki kritik tarih. \u015eirketin 2025 3. \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klamas\u0131 bekleniyor. Tarihsel olarak, bu \u00e7eyreklik raporlar hisse fiyat\u0131n\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde hareket ettirmi\u015ftir.<\/p> <h3>Kazan\u00e7 Raporlar\u0131n\u0131n DCTH Hissesi \u00dczerindeki Etkisi<\/h3> <p>Son performans \u00f6r\u00fcnt\u00fclerine bak\u0131ld\u0131\u011f\u0131nda:<\/p> <table> <thead> <tr><th>Tarih<\/th><th>Olay<\/th><th>Haber \u00d6ncesi Fiyat<\/th><th>Haber Sonras\u0131 De\u011fi\u015fim<\/th><\/tr> <\/thead> <tbody> <tr><td>6 A\u011fu 2025<\/td><td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>13,20 $<\/td><td>%8,3 art\u0131\u015f (1 hafta)<\/td><\/tr> <tr><td>15 May 2025<\/td><td>Klinik Deneme G\u00fcncellemesi<\/td><td>14,80 $<\/td><td>%9,5 art\u0131\u015f (3 g\u00fcn)<\/td><\/tr> <tr><td>28 \u015eub 2025<\/td><td>1. \u00c7eyrek Sonu\u00e7lar\u0131<\/td><td>11,50 $<\/td><td>%12,1 art\u0131\u015f (tahminleri a\u015ft\u0131)<\/td><\/tr> <tr><td>8 Kas 2024<\/td><td>FDA Ba\u015fvurusu<\/td><td>9,75 $<\/td><td>%15,4 art\u0131\u015f (yat\u0131r\u0131mc\u0131 heyecan\u0131)<\/td><\/tr> <tr><td>9 A\u011fu 2024<\/td><td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>10,20 $<\/td><td>%4,2 d\u00fc\u015f\u00fc\u015f (hedefler ka\u00e7\u0131r\u0131ld\u0131)<\/td><\/tr> <tr><td>10 May 2024<\/td><td>Ortakl\u0131k Duyurusu<\/td><td>8,90 $<\/td><td>%18,0 art\u0131\u015f (stratejik anla\u015fma)<\/td><\/tr> <\/tbody> <\/table> <p><strong>Trend Analizi<\/strong>: Pozitif klinik g\u00fcncellemeler ve kazan\u00e7lar\u0131n beklentileri a\u015fmas\u0131 genellikle birka\u00e7 g\u00fcn i\u00e7inde %8-15 fiyat art\u0131\u015f\u0131na yol a\u00e7ar. En dramatik hareketler, \u015firket gelir beklentilerini a\u015ft\u0131\u011f\u0131nda veya yeni tedavi alanlar\u0131na geni\u015fleme duyurdu\u011funda ger\u00e7ekle\u015fir.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Seyri (\u015eubat-A\u011fustos 2025)<\/h2> <p>Delcath hisseleri \u00f6nemli dalgalanmalar ya\u015fad\u0131 ancak genel olarak pozitif bir momentum sergiledi:<\/p> <p><strong>\u015eubat 2025<\/strong>: 9,80 $ (tatil sonras\u0131 konsolidasyon)<br\/> <strong>Mart 2025<\/strong>: 12,73 $ (%29,9 ayl\u0131k art\u0131\u015f)<br\/> <strong>Nisan 2025<\/strong>: 12,04 $ (%5,4 k\u00fc\u00e7\u00fck d\u00fczeltme)<br\/> <strong>May\u0131s 2025<\/strong>: 16,21 $ (%34,6 klinik haberlerle y\u00fckseli\u015f)<br\/> <strong>Haziran 2025<\/strong>: 13,60 $ (%16,1 kar realizasyonu)<br\/> <strong>Temmuz 2025<\/strong>: 12,80 $ (%5,9 yaz yava\u015flamas\u0131)<br\/> <strong>A\u011fustos 2025<\/strong>: 11,12 $ (%13,1 son geri \u00e7ekilme)<\/p> <p><strong>Bu dalgalanman\u0131n nedeni nedir?<\/strong><\/p> <ul> <li>2025 1. ve 2. \u00e7eyrek g\u00fc\u00e7l\u00fc kazan\u00e7lar\u0131, k\u00e2rl\u0131l\u0131\u011fa ge\u00e7i\u015fi g\u00f6steriyor<\/li> <li>HEPZATO KIT tedavi hacmi y\u0131ll\u0131k %200'den fazla b\u00fcy\u00fcyor<\/li> <li>Geri \u00f6deme politikalar\u0131na dair piyasa belirsizli\u011fi<\/li> <li>Klinik deneme a\u015famalar\u0131nda tipik biyoteknoloji hisse volatilitesi<\/li> <\/ul> <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Mevcut analist konsens\u00fcs\u00fc ve \u015firket rehberli\u011fine dayanarak:<\/p> <ul> <li><strong>2025 Y\u0131l Sonu<\/strong>: 24-26 $ (G\u00fc\u00e7l\u00fc gelir b\u00fcy\u00fcmesi + Medicaid eri\u015fiminin geni\u015flemesi) \u2192 <strong>AL<\/strong><\/li> <li><strong>2026 Tahmini<\/strong>: 28-32 $ (mCRC deneme ilerlemesi + uluslararas\u0131 geni\u015fleme)<\/li> <li><strong>2028 Projeksiyonu<\/strong>: 35-42 $ (Potansiyel yeni endikasyonlar + pazar hakimiyeti)<\/li> <li><strong>2030 Vizyonu<\/strong>: 45-55 $ (K\u00fcresel benimseme + platform teknolojisi lisanslamas\u0131)<\/li> <\/ul> <p><strong>Sonu\u00e7<\/strong>: M\u00fckemmel uzun vadeli tutma potansiyeli. Mevcut geri \u00e7ekilme sab\u0131rl\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in cazip giri\u015f noktas\u0131 sunuyor.<\/p> <h2>\u26a0\ufe0f Temel Riskler ve Pozitif \u0130\u015faretler<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3> <ul> <li><strong>Y\u00fcksek volatilite<\/strong>: G\u00fcnl\u00fck %12,18'e varan dalgalanmalar yayg\u0131n<\/li> <li><strong>Tek \u00fcr\u00fcn ba\u011f\u0131ml\u0131l\u0131\u011f\u0131<\/strong>: HEPZATO gelirlerin %90'\u0131ndan fazlas\u0131n\u0131 olu\u015fturuyor<\/li> <li><strong>Reg\u00fclasyon engelleri<\/strong>: Medicaid geri \u00f6deme de\u011fi\u015fiklikleri k\u00e2rl\u0131l\u0131\u011f\u0131 etkileyebilir<\/li> <li><strong>Klinik deneme riskleri<\/strong>: Devam eden \u00e7al\u0131\u015fmalar olumlu sonu\u00e7 vermeyebilir<\/li> <li><strong>Rekabet<\/strong>: Daha b\u00fcy\u00fck ila\u00e7 \u015firketleri benzer teknolojiler geli\u015ftiriyor<\/li> <\/ul> <h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3> <ul> <li><strong>Gelir patlamas\u0131<\/strong>: Y\u0131ll\u0131k %211 b\u00fcy\u00fcme<\/li> <li><strong>K\u00e2rl\u0131l\u0131k sa\u011fland\u0131<\/strong>: Zarar d\u00f6neminden d\u00fczenli k\u00e2rlara ge\u00e7i\u015f<\/li> <li><strong>Analist g\u00fcveni<\/strong>: %120'den fazla y\u00fckseli\u015f hedefiyle G\u00fc\u00e7l\u00fc Al tavsiyeleri<\/li> <li><strong>Pazar geni\u015flemesi<\/strong>: 2025 3. \u00e7eyrekte Medicaid program\u0131na giri\u015f<\/li> <li><strong>Tedavi talebi<\/strong>: HEPZATO hacmi y\u0131ll\u0131k %200 b\u00fcy\u00fcyor<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <p><strong>Ciddi \u00f6neriler:<\/strong><\/p> <ol> <li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong> - Portf\u00f6y\u00fcn\u00fcz\u00fcn %3-5'inden fazlas\u0131n\u0131 y\u00fcksek volatiliteye sahip biyoteknoloji hisselerine ay\u0131rmay\u0131n<\/li> <li><strong>Dolar maliyeti ortalamas\u0131 kullan\u0131n<\/strong> - Tek seferde b\u00fcy\u00fck al\u0131m yerine haftal\u0131k taksitlerle sat\u0131n al\u0131n<\/li> <li><strong>Fiyat uyar\u0131lar\u0131 kurun<\/strong> - Kas\u0131m ay\u0131 kazan\u00e7lar\u0131 \u00e7evresinde potansiyel giri\u015f f\u0131rsatlar\u0131n\u0131 takip edin<\/li> <li><strong>\u0130yi ara\u015ft\u0131r\u0131n<\/strong> - Yat\u0131r\u0131m yapmadan \u00f6nce HEPZATO'nun bilimsel altyap\u0131s\u0131n\u0131 anlay\u0131n<\/li> <\/ol> <p><strong>Esprili deneyimli tavsiye:<\/strong> \"DCTH ticareti k\u00f6r\u00fc k\u00f6r\u00fcne bir lunapark treni s\u00fcrmek gibidir - ini\u015fler i\u00e7in ekstra i\u00e7 \u00e7ama\u015f\u0131r\u0131 almay\u0131 unuttu\u011funuzu fark edene kadar heyecan verici!\"<\/p> <h2>\u2705 Delcath Systems, Inc. (DCTH) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir ticaret platformu se\u00e7in<\/td><td>NASDAQ listeleri ve par\u00e7al\u0131 hisse sunan bir platform oldu\u011fundan emin olun<\/td><\/tr> <tr><td>2<\/td><td>Hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n<\/td><td>\u00c7o\u011fu platform kimlik ve adres kan\u0131t\u0131 ister<\/td><\/tr> <tr><td>3<\/td><td>Fon yat\u0131r\u0131n<\/td><td>Kaybetmeyi g\u00f6ze alabilece\u011finiz bir miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>4<\/td><td>\"DCTH\" aramas\u0131 yap\u0131n<\/td><td>Do\u011fru sonu\u00e7lar i\u00e7in sembol\u00fc kullan\u0131n<\/td><\/tr> <tr><td>5<\/td><td>Sipari\u015f t\u00fcr\u00fcn\u00fc se\u00e7in<\/td><td>Limit emirleri volatilite s\u0131ras\u0131nda fazla \u00f6deme yapman\u0131z\u0131 engeller<\/td><\/tr> <tr><td>6<\/td><td>Sipari\u015f detaylar\u0131n\u0131 g\u00f6zden ge\u00e7irin<\/td><td>Komisyon \u00fccretleri ve takas tarihlerini kontrol edin<\/td><\/tr> <tr><td>7<\/td><td>Sat\u0131n alma i\u015flemini ger\u00e7ekle\u015ftirin<\/td><td>Sipari\u015fi onaylay\u0131n ve fiyat uyar\u0131lar\u0131 kurun<\/td><\/tr> <tr><td>8<\/td><td>Pozisyonu izleyin<\/td><td>Kazan\u00e7 tarihleri ve klinik deneme g\u00fcncellemelerini takip edin<\/td><\/tr> <tr><td>9<\/td><td>Vergi etkilerini de\u011ferlendirin<\/td><td>Sermaye kazanc\u0131 muamelesini anlay\u0131n<\/td><\/tr> <tr><td>10<\/td><td>\u00c7\u0131k\u0131\u015f stratejisi planlay\u0131n<\/td><td>K\u00e2r hedefleri ve zarar durdurma seviyelerini belirleyin<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Neden Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Uygun?<\/h2> <p>Yat\u0131r\u0131m yolculu\u011funa yeni ba\u015flayanlar i\u00e7in Pocket Option, DCTH gibi hisselerde i\u015flem yapmak i\u00e7in \u00e7e\u015fitli avantajlar sunar:<\/p> <ul> <li><strong>Minimum depozito sadece 5 $<\/strong> - Stratejileri d\u00fc\u015f\u00fck riskle test etmek i\u00e7in ideal<\/li> <li><strong>H\u0131zl\u0131 do\u011frulama<\/strong> - Kay\u0131ttan sonra dakikalar i\u00e7inde i\u015flem yapmaya ba\u015flay\u0131n<\/li> <li><strong>Par\u00e7al\u0131 hisse imkan\u0131<\/strong> - Pahal\u0131 hisselerin par\u00e7alar\u0131n\u0131 uygun fiyatla sat\u0131n al\u0131n<\/li> <li><strong>Kullan\u0131c\u0131 dostu platform<\/strong> - Yeni ba\u015flayanlar i\u00e7in tasarlanm\u0131\u015f sezgisel aray\u00fcz<\/li> <li><strong>E\u011fitim kaynaklar\u0131<\/strong> - Portf\u00f6y\u00fcn\u00fcz\u00fc olu\u015ftururken \u00f6\u011frenin<\/li> <\/ul> <h2>\ud83c\udf0d 2025'te Delcath Systems: Onkoloji Yenilik Lideri<\/h2> <p>Delcath Systems, karaci\u011fere y\u00f6nelik kanser tedavileri i\u00e7in ni\u015f ama b\u00fcy\u00fcyen pazarda lider konumdad\u0131r. \u015eirketin HEPZATO KIT\u2122 \u00fcr\u00fcn\u00fc, metastatik uveal melanom tedavisinde \u00e7\u0131\u011f\u0131r a\u00e7an bir yenilik olup, hedefe y\u00f6nelik kemoterapiyi karaci\u011fer t\u00fcm\u00f6rlerine do\u011frudan verirken sistemik yan etkileri en aza indirir.<\/p> <ul> <li><strong>Mevcut pazar konumu<\/strong>: 372 milyon $ piyasa de\u011feri ve %52 kurumsal sahiplik<\/li> <li><strong>Gelir projeksiyonu<\/strong>: 2025 i\u00e7in 94-98 milyon $ (y\u00fczde 150'den fazla b\u00fcy\u00fcme)<\/li> <li><strong>Br\u00fct marjlar<\/strong>: Sekt\u00f6r lideri %83-85 k\u00e2rl\u0131l\u0131k<\/li> <li><strong>Geni\u015fleme stratejisi<\/strong>: Metastatik kolorektal kanser endikasyonu hedefleniyor<\/li> <\/ul> <h3>Klinik M\u00fckemmeliyet<\/h3> <p><em>Annals of Surgical Oncology<\/em> dergisinde yay\u0131mlanan veriler \u015funlar\u0131 g\u00f6steriyor:<\/p> <ul> <li><strong>17,6 ay<\/strong> medyan karaci\u011fer progresyonsuz sa\u011fkal\u0131m, imm\u00fcnoterapiye k\u0131yasla 8,8 ay<\/li> <li><strong>22,4 ay<\/strong> birinci basamak tedavi i\u00e7in genel sa\u011fkal\u0131m<\/li> <li>Mevcut tedavilere k\u0131yasla \u00fcst\u00fcn hastal\u0131k kontrol\u00fc<\/li> <\/ul> <h3>Stratejik Giri\u015fimler<\/h3> <ul> <li><strong>Medicaid eri\u015fimi<\/strong>: 2025 3. \u00e7eyrekte ila\u00e7 geri \u00f6deme program\u0131na giri\u015f<\/li> <li><strong>K\u00fcresel denemeler<\/strong>: mCRC i\u00e7in Faz 2 \u00e7al\u0131\u015fmas\u0131, 90 hasta kayd\u0131<\/li> <li><strong>Pazar geni\u015flemesi<\/strong>: Y\u0131ll\u0131k 6.000-10.000 ek hasta hedefleniyor<\/li> <\/ul> <p><strong>2025'ten \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: Delcath tedavi merkezleri art\u0131k karaci\u011fer t\u00fcm\u00f6r\u00fc kan ak\u0131\u015f\u0131 desenlerini hassas \u015fekilde haritalamak i\u00e7in yapay zeka destekli g\u00f6r\u00fcnt\u00fcleme kullan\u0131yor; bu teknoloji \u015firket sistemini ilk geli\u015ftirdi\u011finde mevcut de\u011fildi!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 G\u00fcncel Hisse Performans\u0131 ve \u00d6nemli Tarihler<\/h2>\n<p>25 A\u011fustos 2025 itibar\u0131yla Delcath Systems, Inc. (DCTH) hissesi <strong>11,12 $<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. Bu fiyat, hissenin 52 haftal\u0131k en y\u00fcksek seviyesi olan 18,23 $&#8217;\u0131n olduk\u00e7a alt\u0131nda ancak y\u0131ll\u0131k en d\u00fc\u015f\u00fck seviyesi olan 7,83 $&#8217;\u0131n \u00fczerinde konumlan\u0131yor.<\/p>\n<p><strong>Takviminize not edin: 14 Kas\u0131m 2025<\/strong>, DCTH yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in bir sonraki kritik tarih. \u015eirketin 2025 3. \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klamas\u0131 bekleniyor. Tarihsel olarak, bu \u00e7eyreklik raporlar hisse fiyat\u0131n\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde hareket ettirmi\u015ftir.<\/p>\n<h3>Kazan\u00e7 Raporlar\u0131n\u0131n DCTH Hissesi \u00dczerindeki Etkisi<\/h3>\n<p>Son performans \u00f6r\u00fcnt\u00fclerine bak\u0131ld\u0131\u011f\u0131nda:<\/p>\n<table>\n<thead>\n<tr>\n<th>Tarih<\/th>\n<th>Olay<\/th>\n<th>Haber \u00d6ncesi Fiyat<\/th>\n<th>Haber Sonras\u0131 De\u011fi\u015fim<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>6 A\u011fu 2025<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>13,20 $<\/td>\n<td>%8,3 art\u0131\u015f (1 hafta)<\/td>\n<\/tr>\n<tr>\n<td>15 May 2025<\/td>\n<td>Klinik Deneme G\u00fcncellemesi<\/td>\n<td>14,80 $<\/td>\n<td>%9,5 art\u0131\u015f (3 g\u00fcn)<\/td>\n<\/tr>\n<tr>\n<td>28 \u015eub 2025<\/td>\n<td>1. \u00c7eyrek Sonu\u00e7lar\u0131<\/td>\n<td>11,50 $<\/td>\n<td>%12,1 art\u0131\u015f (tahminleri a\u015ft\u0131)<\/td>\n<\/tr>\n<tr>\n<td>8 Kas 2024<\/td>\n<td>FDA Ba\u015fvurusu<\/td>\n<td>9,75 $<\/td>\n<td>%15,4 art\u0131\u015f (yat\u0131r\u0131mc\u0131 heyecan\u0131)<\/td>\n<\/tr>\n<tr>\n<td>9 A\u011fu 2024<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>10,20 $<\/td>\n<td>%4,2 d\u00fc\u015f\u00fc\u015f (hedefler ka\u00e7\u0131r\u0131ld\u0131)<\/td>\n<\/tr>\n<tr>\n<td>10 May 2024<\/td>\n<td>Ortakl\u0131k Duyurusu<\/td>\n<td>8,90 $<\/td>\n<td>%18,0 art\u0131\u015f (stratejik anla\u015fma)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Trend Analizi<\/strong>: Pozitif klinik g\u00fcncellemeler ve kazan\u00e7lar\u0131n beklentileri a\u015fmas\u0131 genellikle birka\u00e7 g\u00fcn i\u00e7inde %8-15 fiyat art\u0131\u015f\u0131na yol a\u00e7ar. En dramatik hareketler, \u015firket gelir beklentilerini a\u015ft\u0131\u011f\u0131nda veya yeni tedavi alanlar\u0131na geni\u015fleme duyurdu\u011funda ger\u00e7ekle\u015fir.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Seyri (\u015eubat-A\u011fustos 2025)<\/h2>\n<p>Delcath hisseleri \u00f6nemli dalgalanmalar ya\u015fad\u0131 ancak genel olarak pozitif bir momentum sergiledi:<\/p>\n<p><strong>\u015eubat 2025<\/strong>: 9,80 $ (tatil sonras\u0131 konsolidasyon)<br \/> <strong>Mart 2025<\/strong>: 12,73 $ (%29,9 ayl\u0131k art\u0131\u015f)<br \/> <strong>Nisan 2025<\/strong>: 12,04 $ (%5,4 k\u00fc\u00e7\u00fck d\u00fczeltme)<br \/> <strong>May\u0131s 2025<\/strong>: 16,21 $ (%34,6 klinik haberlerle y\u00fckseli\u015f)<br \/> <strong>Haziran 2025<\/strong>: 13,60 $ (%16,1 kar realizasyonu)<br \/> <strong>Temmuz 2025<\/strong>: 12,80 $ (%5,9 yaz yava\u015flamas\u0131)<br \/> <strong>A\u011fustos 2025<\/strong>: 11,12 $ (%13,1 son geri \u00e7ekilme)<\/p>\n<p><strong>Bu dalgalanman\u0131n nedeni nedir?<\/strong><\/p>\n<ul>\n<li>2025 1. ve 2. \u00e7eyrek g\u00fc\u00e7l\u00fc kazan\u00e7lar\u0131, k\u00e2rl\u0131l\u0131\u011fa ge\u00e7i\u015fi g\u00f6steriyor<\/li>\n<li>HEPZATO KIT tedavi hacmi y\u0131ll\u0131k %200&#8217;den fazla b\u00fcy\u00fcyor<\/li>\n<li>Geri \u00f6deme politikalar\u0131na dair piyasa belirsizli\u011fi<\/li>\n<li>Klinik deneme a\u015famalar\u0131nda tipik biyoteknoloji hisse volatilitesi<\/li>\n<\/ul>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Mevcut analist konsens\u00fcs\u00fc ve \u015firket rehberli\u011fine dayanarak:<\/p>\n<ul>\n<li><strong>2025 Y\u0131l Sonu<\/strong>: 24-26 $ (G\u00fc\u00e7l\u00fc gelir b\u00fcy\u00fcmesi + Medicaid eri\u015fiminin geni\u015flemesi) \u2192 <strong>AL<\/strong><\/li>\n<li><strong>2026 Tahmini<\/strong>: 28-32 $ (mCRC deneme ilerlemesi + uluslararas\u0131 geni\u015fleme)<\/li>\n<li><strong>2028 Projeksiyonu<\/strong>: 35-42 $ (Potansiyel yeni endikasyonlar + pazar hakimiyeti)<\/li>\n<li><strong>2030 Vizyonu<\/strong>: 45-55 $ (K\u00fcresel benimseme + platform teknolojisi lisanslamas\u0131)<\/li>\n<\/ul>\n<p><strong>Sonu\u00e7<\/strong>: M\u00fckemmel uzun vadeli tutma potansiyeli. Mevcut geri \u00e7ekilme sab\u0131rl\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in cazip giri\u015f noktas\u0131 sunuyor.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Pozitif \u0130\u015faretler<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3>\n<ul>\n<li><strong>Y\u00fcksek volatilite<\/strong>: G\u00fcnl\u00fck %12,18&#8217;e varan dalgalanmalar yayg\u0131n<\/li>\n<li><strong>Tek \u00fcr\u00fcn ba\u011f\u0131ml\u0131l\u0131\u011f\u0131<\/strong>: HEPZATO gelirlerin %90&#8217;\u0131ndan fazlas\u0131n\u0131 olu\u015fturuyor<\/li>\n<li><strong>Reg\u00fclasyon engelleri<\/strong>: Medicaid geri \u00f6deme de\u011fi\u015fiklikleri k\u00e2rl\u0131l\u0131\u011f\u0131 etkileyebilir<\/li>\n<li><strong>Klinik deneme riskleri<\/strong>: Devam eden \u00e7al\u0131\u015fmalar olumlu sonu\u00e7 vermeyebilir<\/li>\n<li><strong>Rekabet<\/strong>: Daha b\u00fcy\u00fck ila\u00e7 \u015firketleri benzer teknolojiler geli\u015ftiriyor<\/li>\n<\/ul>\n<h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3>\n<ul>\n<li><strong>Gelir patlamas\u0131<\/strong>: Y\u0131ll\u0131k %211 b\u00fcy\u00fcme<\/li>\n<li><strong>K\u00e2rl\u0131l\u0131k sa\u011fland\u0131<\/strong>: Zarar d\u00f6neminden d\u00fczenli k\u00e2rlara ge\u00e7i\u015f<\/li>\n<li><strong>Analist g\u00fcveni<\/strong>: %120&#8217;den fazla y\u00fckseli\u015f hedefiyle G\u00fc\u00e7l\u00fc Al tavsiyeleri<\/li>\n<li><strong>Pazar geni\u015flemesi<\/strong>: 2025 3. \u00e7eyrekte Medicaid program\u0131na giri\u015f<\/li>\n<li><strong>Tedavi talebi<\/strong>: HEPZATO hacmi y\u0131ll\u0131k %200 b\u00fcy\u00fcyor<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<p><strong>Ciddi \u00f6neriler:<\/strong><\/p>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong> &#8211; Portf\u00f6y\u00fcn\u00fcz\u00fcn %3-5&#8217;inden fazlas\u0131n\u0131 y\u00fcksek volatiliteye sahip biyoteknoloji hisselerine ay\u0131rmay\u0131n<\/li>\n<li><strong>Dolar maliyeti ortalamas\u0131 kullan\u0131n<\/strong> &#8211; Tek seferde b\u00fcy\u00fck al\u0131m yerine haftal\u0131k taksitlerle sat\u0131n al\u0131n<\/li>\n<li><strong>Fiyat uyar\u0131lar\u0131 kurun<\/strong> &#8211; Kas\u0131m ay\u0131 kazan\u00e7lar\u0131 \u00e7evresinde potansiyel giri\u015f f\u0131rsatlar\u0131n\u0131 takip edin<\/li>\n<li><strong>\u0130yi ara\u015ft\u0131r\u0131n<\/strong> &#8211; Yat\u0131r\u0131m yapmadan \u00f6nce HEPZATO&#8217;nun bilimsel altyap\u0131s\u0131n\u0131 anlay\u0131n<\/li>\n<\/ol>\n<p><strong>Esprili deneyimli tavsiye:<\/strong> &#8220;DCTH ticareti k\u00f6r\u00fc k\u00f6r\u00fcne bir lunapark treni s\u00fcrmek gibidir &#8211; ini\u015fler i\u00e7in ekstra i\u00e7 \u00e7ama\u015f\u0131r\u0131 almay\u0131 unuttu\u011funuzu fark edene kadar heyecan verici!&#8221;<\/p>\n<h2>\u2705 Delcath Systems, Inc. (DCTH) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir ticaret platformu se\u00e7in<\/td>\n<td>NASDAQ listeleri ve par\u00e7al\u0131 hisse sunan bir platform oldu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n<\/td>\n<td>\u00c7o\u011fu platform kimlik ve adres kan\u0131t\u0131 ister<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Fon yat\u0131r\u0131n<\/td>\n<td>Kaybetmeyi g\u00f6ze alabilece\u011finiz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>&#8220;DCTH&#8221; aramas\u0131 yap\u0131n<\/td>\n<td>Do\u011fru sonu\u00e7lar i\u00e7in sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Sipari\u015f t\u00fcr\u00fcn\u00fc se\u00e7in<\/td>\n<td>Limit emirleri volatilite s\u0131ras\u0131nda fazla \u00f6deme yapman\u0131z\u0131 engeller<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Sipari\u015f detaylar\u0131n\u0131 g\u00f6zden ge\u00e7irin<\/td>\n<td>Komisyon \u00fccretleri ve takas tarihlerini kontrol edin<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Sat\u0131n alma i\u015flemini ger\u00e7ekle\u015ftirin<\/td>\n<td>Sipari\u015fi onaylay\u0131n ve fiyat uyar\u0131lar\u0131 kurun<\/td>\n<\/tr>\n<tr>\n<td>8<\/td>\n<td>Pozisyonu izleyin<\/td>\n<td>Kazan\u00e7 tarihleri ve klinik deneme g\u00fcncellemelerini takip edin<\/td>\n<\/tr>\n<tr>\n<td>9<\/td>\n<td>Vergi etkilerini de\u011ferlendirin<\/td>\n<td>Sermaye kazanc\u0131 muamelesini anlay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>10<\/td>\n<td>\u00c7\u0131k\u0131\u015f stratejisi planlay\u0131n<\/td>\n<td>K\u00e2r hedefleri ve zarar durdurma seviyelerini belirleyin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Neden Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Uygun?<\/h2>\n<p>Yat\u0131r\u0131m yolculu\u011funa yeni ba\u015flayanlar i\u00e7in Pocket Option, DCTH gibi hisselerde i\u015flem yapmak i\u00e7in \u00e7e\u015fitli avantajlar sunar:<\/p>\n<ul>\n<li><strong>Minimum depozito sadece 5 $<\/strong> &#8211; Stratejileri d\u00fc\u015f\u00fck riskle test etmek i\u00e7in ideal<\/li>\n<li><strong>H\u0131zl\u0131 do\u011frulama<\/strong> &#8211; Kay\u0131ttan sonra dakikalar i\u00e7inde i\u015flem yapmaya ba\u015flay\u0131n<\/li>\n<li><strong>Par\u00e7al\u0131 hisse imkan\u0131<\/strong> &#8211; Pahal\u0131 hisselerin par\u00e7alar\u0131n\u0131 uygun fiyatla sat\u0131n al\u0131n<\/li>\n<li><strong>Kullan\u0131c\u0131 dostu platform<\/strong> &#8211; Yeni ba\u015flayanlar i\u00e7in tasarlanm\u0131\u015f sezgisel aray\u00fcz<\/li>\n<li><strong>E\u011fitim kaynaklar\u0131<\/strong> &#8211; Portf\u00f6y\u00fcn\u00fcz\u00fc olu\u015ftururken \u00f6\u011frenin<\/li>\n<\/ul>\n<h2>\ud83c\udf0d 2025&#8217;te Delcath Systems: Onkoloji Yenilik Lideri<\/h2>\n<p>Delcath Systems, karaci\u011fere y\u00f6nelik kanser tedavileri i\u00e7in ni\u015f ama b\u00fcy\u00fcyen pazarda lider konumdad\u0131r. \u015eirketin HEPZATO KIT\u2122 \u00fcr\u00fcn\u00fc, metastatik uveal melanom tedavisinde \u00e7\u0131\u011f\u0131r a\u00e7an bir yenilik olup, hedefe y\u00f6nelik kemoterapiyi karaci\u011fer t\u00fcm\u00f6rlerine do\u011frudan verirken sistemik yan etkileri en aza indirir.<\/p>\n<ul>\n<li><strong>Mevcut pazar konumu<\/strong>: 372 milyon $ piyasa de\u011feri ve %52 kurumsal sahiplik<\/li>\n<li><strong>Gelir projeksiyonu<\/strong>: 2025 i\u00e7in 94-98 milyon $ (y\u00fczde 150&#8217;den fazla b\u00fcy\u00fcme)<\/li>\n<li><strong>Br\u00fct marjlar<\/strong>: Sekt\u00f6r lideri %83-85 k\u00e2rl\u0131l\u0131k<\/li>\n<li><strong>Geni\u015fleme stratejisi<\/strong>: Metastatik kolorektal kanser endikasyonu hedefleniyor<\/li>\n<\/ul>\n<h3>Klinik M\u00fckemmeliyet<\/h3>\n<p><em>Annals of Surgical Oncology<\/em> dergisinde yay\u0131mlanan veriler \u015funlar\u0131 g\u00f6steriyor:<\/p>\n<ul>\n<li><strong>17,6 ay<\/strong> medyan karaci\u011fer progresyonsuz sa\u011fkal\u0131m, imm\u00fcnoterapiye k\u0131yasla 8,8 ay<\/li>\n<li><strong>22,4 ay<\/strong> birinci basamak tedavi i\u00e7in genel sa\u011fkal\u0131m<\/li>\n<li>Mevcut tedavilere k\u0131yasla \u00fcst\u00fcn hastal\u0131k kontrol\u00fc<\/li>\n<\/ul>\n<h3>Stratejik Giri\u015fimler<\/h3>\n<ul>\n<li><strong>Medicaid eri\u015fimi<\/strong>: 2025 3. \u00e7eyrekte ila\u00e7 geri \u00f6deme program\u0131na giri\u015f<\/li>\n<li><strong>K\u00fcresel denemeler<\/strong>: mCRC i\u00e7in Faz 2 \u00e7al\u0131\u015fmas\u0131, 90 hasta kayd\u0131<\/li>\n<li><strong>Pazar geni\u015flemesi<\/strong>: Y\u0131ll\u0131k 6.000-10.000 ek hasta hedefleniyor<\/li>\n<\/ul>\n<p><strong>2025&#8217;ten \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: Delcath tedavi merkezleri art\u0131k karaci\u011fer t\u00fcm\u00f6r\u00fc kan ak\u0131\u015f\u0131 desenlerini hassas \u015fekilde haritalamak i\u00e7in yapay zeka destekli g\u00f6r\u00fcnt\u00fcleme kullan\u0131yor; bu teknoloji \u015firket sistemini ilk geli\u015ftirdi\u011finde mevcut de\u011fildi!<\/p>\n"},"faq":[{"question":"Delcath Systems, Inc. hisseleri nereden al\u0131nabilir?","answer":"Delcath Systems, Inc. hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir ve bir\u00e7ok \u00e7evrimi\u00e7i arac\u0131 kurum ve ticaret platformu \u00fczerinden sat\u0131n al\u0131nabilir."},{"question":"Delcath hisseleri almak i\u00e7in minimum yat\u0131r\u0131m tutar\u0131 nedir?","answer":"Minimum yat\u0131r\u0131m tutar\u0131 se\u00e7ilen platforma ba\u011fl\u0131d\u0131r ancak Pocket Option gibi platformlarda 5 $ gibi d\u00fc\u015f\u00fck depozito ile ba\u015flayabilirsiniz."},{"question":"Delcath Systems, Inc. hisselerinin riskleri nelerdir?","answer":"Y\u00fcksek volatilite, tek \u00fcr\u00fcn ba\u011f\u0131ml\u0131l\u0131\u011f\u0131, reg\u00fclasyon de\u011fi\u015fiklikleri ve klinik deneme sonu\u00e7lar\u0131na ba\u011fl\u0131 riskler ba\u015fl\u0131ca risklerdir."},{"question":"Delcath hisseleri i\u00e7in uzun vadeli fiyat tahmini nedir?","answer":"Analistlere g\u00f6re 2025 sonunda 24-26 $, 2030 y\u0131l\u0131nda ise 45-55 $ aras\u0131nda fiyatlar beklenmektedir."},{"question":"Yeni ba\u015flayanlar Delcath hissesi al\u0131rken nelere dikkat etmeli?","answer":"Portf\u00f6y\u00fcn k\u00fc\u00e7\u00fck bir y\u00fczdesiyle ba\u015flay\u0131p, dolar maliyeti ortalamas\u0131 yaparak, fiyat uyar\u0131lar\u0131 kurarak ve \u015firketin tedavi teknolojisini iyi ara\u015ft\u0131rarak yat\u0131r\u0131m yapmalar\u0131 \u00f6nerilir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Delcath Systems, Inc. hisseleri nereden al\u0131nabilir?","answer":"Delcath Systems, Inc. hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir ve bir\u00e7ok \u00e7evrimi\u00e7i arac\u0131 kurum ve ticaret platformu \u00fczerinden sat\u0131n al\u0131nabilir."},{"question":"Delcath hisseleri almak i\u00e7in minimum yat\u0131r\u0131m tutar\u0131 nedir?","answer":"Minimum yat\u0131r\u0131m tutar\u0131 se\u00e7ilen platforma ba\u011fl\u0131d\u0131r ancak Pocket Option gibi platformlarda 5 $ gibi d\u00fc\u015f\u00fck depozito ile ba\u015flayabilirsiniz."},{"question":"Delcath Systems, Inc. hisselerinin riskleri nelerdir?","answer":"Y\u00fcksek volatilite, tek \u00fcr\u00fcn ba\u011f\u0131ml\u0131l\u0131\u011f\u0131, reg\u00fclasyon de\u011fi\u015fiklikleri ve klinik deneme sonu\u00e7lar\u0131na ba\u011fl\u0131 riskler ba\u015fl\u0131ca risklerdir."},{"question":"Delcath hisseleri i\u00e7in uzun vadeli fiyat tahmini nedir?","answer":"Analistlere g\u00f6re 2025 sonunda 24-26 $, 2030 y\u0131l\u0131nda ise 45-55 $ aras\u0131nda fiyatlar beklenmektedir."},{"question":"Yeni ba\u015flayanlar Delcath hissesi al\u0131rken nelere dikkat etmeli?","answer":"Portf\u00f6y\u00fcn k\u00fc\u00e7\u00fck bir y\u00fczdesiyle ba\u015flay\u0131p, dolar maliyeti ortalamas\u0131 yaparak, fiyat uyar\u0131lar\u0131 kurarak ve \u015firketin tedavi teknolojisini iyi ara\u015ft\u0131rarak yat\u0131r\u0131m yapmalar\u0131 \u00f6nerilir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Delcath Systems, Inc. (DCTH) Hisseleri Nas\u0131l Al\u0131n\u0131r - Delcath Systems, Inc. (DCTH) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-delcath-systems\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Delcath Systems, Inc. (DCTH) Hisseleri Nas\u0131l Al\u0131n\u0131r - Delcath Systems, Inc. (DCTH) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-delcath-systems\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T14:30:20+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-delcath-systems\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-delcath-systems\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Delcath Systems, Inc. (DCTH) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Delcath Systems, Inc. (DCTH) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-25T14:30:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-delcath-systems\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-delcath-systems\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-delcath-systems\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-delcath-systems\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-delcath-systems\/\",\"name\":\"Delcath Systems, Inc. (DCTH) Hisseleri Nas\u0131l Al\u0131n\u0131r - Delcath Systems, Inc. (DCTH) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-delcath-systems\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-delcath-systems\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"datePublished\":\"2025-08-25T14:30:20+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-delcath-systems\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-delcath-systems\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-delcath-systems\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-delcath-systems\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Delcath Systems, Inc. (DCTH) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Delcath Systems, Inc. (DCTH) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Delcath Systems, Inc. (DCTH) Hisseleri Nas\u0131l Al\u0131n\u0131r - Delcath Systems, Inc. (DCTH) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-delcath-systems\/","og_locale":"tr_TR","og_type":"article","og_title":"Delcath Systems, Inc. (DCTH) Hisseleri Nas\u0131l Al\u0131n\u0131r - Delcath Systems, Inc. (DCTH) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-delcath-systems\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T14:30:20+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-delcath-systems\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-delcath-systems\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Delcath Systems, Inc. (DCTH) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Delcath Systems, Inc. (DCTH) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-25T14:30:20+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-delcath-systems\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-delcath-systems\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-delcath-systems\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-delcath-systems\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-delcath-systems\/","name":"Delcath Systems, Inc. (DCTH) Hisseleri Nas\u0131l Al\u0131n\u0131r - Delcath Systems, Inc. (DCTH) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-delcath-systems\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-delcath-systems\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","datePublished":"2025-08-25T14:30:20+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-delcath-systems\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-delcath-systems\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-delcath-systems\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-delcath-systems\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Delcath Systems, Inc. (DCTH) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Delcath Systems, Inc. (DCTH) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":348455,"slug":"how-to-buy-delcath-systems","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Delcath Systems, Inc. (DCTH) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Delcath Systems, Inc. (DCTH)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-delcath-systems\/"},"pt_AA":{"locale":"pt_AA","id":348449,"slug":"how-to-buy-delcath-systems","post_title":"Como comprar a\u00e7\u00f5es da Delcath Systems, Inc. (DCTH) - Investimento em a\u00e7\u00f5es da Delcath Systems, Inc. (DCTH)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-delcath-systems\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/348452","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=348452"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/348452\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334054"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=348452"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=348452"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=348452"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}